VLPbio, the vacines company

Focused on research and development of Chimeric Virus like Particles (VLPs) as vaccines in Animal and Human Health

VLPbio, the vacines company

Focused on research and development of Chimeric Virus like Particles (VLPs) as vaccines in Animal and Human Health

VLPbio, the vacines company

Focused on research and development of Chimeric Virus like Particles (VLPs) as vaccines in Animal and Human Health

 

Who we are?

We are a biotechnological company applying immunotherapeutic solutions to fight cancer and infectious diseases, addressing unmet medical needs in the main human and veterinarian markets

Our mission

Development of innovative vaccines for the world’s animal and human health markets, based on the platform protected and proprietary VLP

Our history

Since 2011 we are woking in the development of vaccines with 3 family patents applied, in-vivo proof of concepts, and now launching products both in Animal and Human Health

Technology platform

Our technology is a patented and proprietary antigen-display nanoplatform based on VLPs. These are empty and non infectious structures mimicking real viruses and then capable to induce strong immune responses

Opportunity

Our C-VLPs could be ideal vehicles to generate vaccines against animal pathologies in which protection is dependent on one or few well-known epitopes

The VLP Technology

Our technology is a patented and proprietary antigen-display nanoplatform based on Virus-Like Particles (VLPs). These are empty and non infectious structures mimicking real viruses and then capable to induce strong immune responses. We are able to incorporate pathology-associated antigens into VLPs generating chimeric nanoparticles (Ch-VLPs) that can be designed to specifically induce either humoral or cellular responses.

Advantages of VLPbio technology

  • Biosafety: VLPs mimic real viruses but they are not infectious avoiding the issues related to pathogen inactivation and simplifying vaccines security tests
  • High flexibility: Vaccines can be constituted by a formulation of different Ch-VLPs monocomponents displaying different antigens (cellular, humoral or both)
  • Synthetic Design: Possibility to design synthetic antigenic consensus sequences covering different pathogen strains
  • Compilance (DIVA)
  • Low cost production
  • Co-development of diagnostic tests

Our Products

Animal Health

PRRSVax

Prophylactic vaccine against porcine reproductive respiratory syndrome

MORE INFO

Others

Circovirus y BDV

Human Health

CerVivax

Proprietary therapeutic Vaccine against Cervical Intrauterine Neoplastia based on Q-VLP proprietary technology

MORE INFO

We offer customized solutions

Contact us to discuss your project

Visit us

C/ Louis Proust, 13

47151 Boecillo (Valladolid)

Spain

Call us

(+34) 983 010 722

Send a message

info@bdibiotech.co

 

Follow us